Search
Arvinas Inc
ARVNAdd to Watchlist
7.730USD
+0.060+0.78%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
498.58MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Arvinas Inc is 7.40, ranking 295 out of 389 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 21.00 and a low of 6.00.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
15.400
Target Price
+100.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Arvinas Inc
ARVN
18
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Arvinas Inc's expected revenue for the next quarter?
Arvinas Inc's expected revenue is 35.54M.
What is Arvinas Inc's price target?
Analysts forecast that Arvinas Inc's price target is USD 14.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 6.00.
How have Arvinas IncARVN's recent earnings per share performed?
The market expectation was USD -0.90, while Arvinas IncARVN's earnings per share (EPS) for the previous quarter was USD -1.04. EPS for the next quarter is expected at USD -0.54.
What is the analyst rating for Arvinas Inc?
Based on the ratings of Arvinas Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
